All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma

Intensive induction shows greater remission rates and better OS compared to nonintensive induction for patients with intermediate- or adverse-risk AML

Feb 24, 2022

During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, presented results from the study Connect® Myeloid Disease Registry (NCT01688011), investigating post remission treatment patterns and outcomes for patients with acute myeloid leukemia (AML) in a real-world cohort.1 Remission and overall survival (OS) rates remain low in AML despite advances in treatment options.

Study design

The large, prospective, multicenter, observational cohort included patients aged ≥55 years who had been diagnosed with AML within 60 days of enrolment. Patient categories were set out according to the European LeukemiaNet (ELN) 2010 genetic prognostic factor: favorable; intermediate; adverse.


Across a total of 706 patients, 313 received intensive therapy and 393 received nonintensive therapy. The median OS by age and ELN 2010 category is shown in Table 1.

Table 1. Median OS across both treatment groups*

Median OS,
months (95% CI)

Intensive therapy
(n = 313)

Nonintensive therapy
(n = 393)

Whole group

22 (18–29)

11 (9–13)

By age

              <60 years

38 (23–NE)

16 (9–NE)

              ≥60 to <70 years

24 (17–40)

13 (8–18)

              ≥70 years

14 (9–21)

10 (9–13)

By ELN 2010 risk


54 (34–NE)

16 (6–NE)


26 (21–38)

14 (11–17)


8 (7–11)

6 (5–8)

ELN, European LeukemiaNet; NE, not evaluable; OS, overall survival.
*Adapted from Roboz et al.1

The most common consolidation therapy for patients in the intermediate-/adverse-risk categories was cytarabine. 42 (54.5%) patients in the intermediate-/adverse-risk categories who received consolidation underwent transplantation, compared to 8 (22.8%) patients with favorable risk. The median time from first remission to transplantation was 3.8 months for patients in the intermediate-/adverse-risk categories, compared to 9.6 months for those in the favorable risk. The number of patients who achieved remission for each treatment group is shown in Figure 1.

Figure 1. Patients who achieved remission*

*Adapted from Roboz et al.1

 Among the 261 patients achieving remission regardless of therapy, 161 had intermediate/adverse risk. Among these patients, 100 were not suitable for transplant due to age, comorbidities, and performance status. Most patients who did not undergo transplantation had some type of post remission therapy (see Table 2).

Table 2. Post remission therapy for patients who did not undergo transplantation*

Post remission therapy

Patients, n
(n = 100)

Consolidation—intensive chemotherapy


Prolonged therapy—ongoing therapy with similar agents used in low-intensity induction


Maintenance therapy—low-intensity agent not used during induction or consolidation


No post remission therapy


*Adapted from Roboz et al.1


Treatment outcomes were consistent with expectations based on published data. Patients with ELN intermediate/adverse risk were unable to receive a transplant and, therefore, continued to have poor OS despite receiving post remission therapy.

  1. Roboz G, Abedi M, Thompson MA, et al. Treatment patterns and survival outcomes of patients with acute myeloid leukemia who achieved remission in the Connect® Myeloid Disease Registry. Oral abstract #279. 63rd ASH Annual Meeting and Exposition; Dec 12, 2021; Atlanta, US.